NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.

BROS targets 2,029 shops by 2029 as expansion accelerates, backed by site strategy and strong same-shop sales.

IRDM's steady earnings growth, defense ties and lower valuation may give it an edge over high-flying ASTS.

ARGYLE, Texas, June 17, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced its newest community, Enclave at Hickory Hill , is coming soon to Argyle, Texas. This exclusive Dallas-area community will feature new luxury homes on spacious one-acre home sites, offering an exceptional living experience in Denton County. Site work is underway, and the community is anticipated to open for sale in fall 2025.

Transaction highlights strategic execution and unlocks capital for highly accretive Spetner Acquisition Transaction highlights strategic execution and unlocks capital for highly accretive Spetner Acquisition

Hilton Worldwide gets a buy rating, after presenting much more upside factors than downside in my 6-point rating approach. A growing portfolio of rooms, strong profit margins in its sector, and continued penetration in Europe and Asia markets are impressive points. The dividend made a nice recovery after taking a dip during the pandemic years, as operating cashflow keeps growing to support it.

Chevron Corporation (NYSE:CVX, ETR:CHV) is getting into the lithium business with the acquisition of two leasehold acreage positions in Texas and Arkansas. The move follows ExxonMobil's efforts to establish a domestic lithium business.

Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Eli Lilly announced on Monday it will soon make the two highest doses of its popular weight-loss drug Zepbound available for self-paying customers on its website.

I'm still bullish on Amprius, although I downgraded my strong buy to a buy due to recent price action and the high chance for an equity financing round. I see triple-digit yoy revenue growth in 2025, driven by the remaining part of the $20 million LEV deal and new aerospace orders, including the $15 million UAS contract. I anticipate further contract wins this year in the UAS and light EV markets, with a good chance to break the $4 resistance on new deal announcements.

Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

IONQ bets on Lightsynq and Capella to scale quantum systems and build secure global quantum networks.

Juniper is likely to edge out Arista as a better cloud networking play for 2025, thanks to stronger EPS growth and valuation upside.

MO's smoke-free push is under threat as illicit flavored e-vapor products dominate a growing U.S. nicotine market.

SMR gains momentum as demand for carbon-free energy rises and top tech firms back its small modular reactor tech.

Ainos Hits Inflection Point with AI Nose Pilot Ramp in Senior Care, Robotics, and Semiconductors Key VELDONA® Human Clinical Studies Secure Taiwan Regulatory Greenlight, Accelerating Development SAN DIEGO, CA / ACCESS Newswire / June 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting Ainos' critical milestones and strategic advancements in 1H25, and its robust roadmap for the remainder of the year, with multiple large scale AI Nose pilot programs and Veldona ® clinical trials on deck. Key Highlights from the Report: …

Shell is a diversified energy leader, excelling in LNG, oil, and renewables, with a focus on margin and efficiency under new management. Q1 2025 results showed strong profit growth, driven by LNG and gas, with stable margins and improved shareholder returns through dividends and buybacks. Shares remain undervalued by 5-10% versus sector peers, supported by predictable cash flows, disciplined capex, and a conservative financial model.

AGNC's 15.43% yield and rising NII look appealing, but its premium valuation and mortgage market risks suggest caution. Let us find out.

Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.

Wells Fargo shared concerns for Tesla (TSLA), citing flat second-quarter vehicle deliveries compared to weaker numbers in the first quarter. With the company's tentative robotaxi launch scheduled this Sunday, George Tsilis says the pressure is on for Tesla to deliver.